Preview

Медицинский Совет

Расширенный поиск

«Парадокс холестерина» у пациентов с хронической сердечной недостаточностью. Современное состояние проблемы

https://doi.org/10.21518/2079-701X-2016-13-61-65

Полный текст:

Аннотация

Хроническая сердечная недостаточность (ХСН) – распространенное заболевание среди населения Российской Федерации и, как правило, связана с наличием ишемической болезни сердца (ИБС). Гиперхолестеринемия является основным фактором риска развития ИБС, но, как это ни парадоксально, у пациентов с ХСН часто определяется низкий уровень холестерина, что, в свою очередь, связано с плохим прогнозом. Уменьшение уровня холестерина статинами снижает заболеваемость и смертность у пациентов с ИБС, не имеющих ХСН, и, возможно, также улучшает прогноз у больных с ХСН. Однако результаты ряда исследований свидетельствуют о том, что высокий уровень холестерина у пациентов с ХСН ассоциируется с лучшими показателями выживаемости. В данной статье рассматривается «парадокс холестерина» у пациентов с ХСН, возможные его механизмы и современные алгоритмы ведения указанной группы больных.

Об авторе

Р. Н. ШЕПЕЛЬ
Государственный научно-исследовательский центр профилактической медицины Минздрава России
Россия
Москва


Список литературы

1. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990, 322: 1700-1707.

2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J, 1991, 121: 951-957.

3. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail, 1997, 3: 249-254.

4. Vredevoe DL, Woo MA, Doering LV et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1998, 82(3): 323-328.

5. Richartz BM, Radovancevic B, Frazier OH et al. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology, 1998, 89(3): 184-188.

6. Rauchhaus M, Koloczek V, Volk H et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol, 2000, 76(2–3): 125-33.

7. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 2(11): 1933-1940.

8. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J, 2006, 152(6): 1077-1083.

9. May HT, Muhlestein JB, Carlquist JF et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol, 2006, 98: 653- 658.

10. Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.

11. Freitas HF, Barbosa EA, Rosa FH et al. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res, 2009, 42(5): 420-405.

12. Horwich TB, Hernandez AZ et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J, 2008, 156(6): 1170-1076.

13. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis, 2011, 70: 482-487.

14. Yoon CH, Youn TJ, Ahn S et al. Korean Heart Failure Registry. Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry. J Card Fail, 2012, 18(3): 194-201.

15. Volpato S, Leveille SG, Corti MC et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49: 1142-1147.

16. Volpato S, Zuliani G, Guralnik JM et al. The inverse association between age and cholesterol level among older patients: The role of poor health status. Gerontology, 2001, 47: 36-45.

17. Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart diseaёse mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA, 1994, 272: 1335-1340.

18. Bonilla-Palomas JL, Gámez-López AL, Moreno- Conde M et al. Total cholesterol levels predict inhospital mortality in patients with acute heart failure aged 70 years or older. Rev Esp Geriatr Gerontol, 2016, 13. pii: S0211-139X(15)00238-3.

19. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther, 2003, 99(1): 95-112.

20. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344 (8934): 1383-1389.

21. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333(20): 1301-1307.

22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339(19): 1349-1357.

23. Anker SD, Chua TP, Swan JW. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure. The importance for cardiac cachexia. Circulation, 1997, 96: 526-534.

24. Pasini E, Aquilani R, Gheorghiade M et al. Malnutrition, muscle wasting and cachexia in chronic heart failure: The nutritional approach. Ital Heart J, 2003, 4: 232-235.

25. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997, 349: 1050-1053.

26. Witte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol, 2002, 85: 23-31.

27. Anker SD, Coats AJ. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest, 1999, 115: 836-847.

28. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 1997, 96: 526-534.

29. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 42: 1933-1940.

30. Mortensen SA, Leth A, Agner E, Rohde M. Doserelated decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med, 1997, 18(Suppl): S137-S144.

31. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet, 2004, 363(9412): 892-894.

32. Драпкина О.М., Шепель Р.Н. Статины и риск развития инфекционных заболеваний. Рациональная фармакотерапия в кардиологии, 2013, 9(3): 306-310./ Drapkina O.M., Shepel R.N. Statins and risk of infectious diseases development. Ratsionalnaya farmakoterapia v kardiologii, 2013, 9 (3): 306-310.

33. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure, Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail, 2005, 7: 1059-69.

34. GISSIР-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSIРHF trial): a randomized, doubleР blind, placeboРcontrolled trial. Lancet, 2008, 372: 1231-1239.

35. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 81(7): 379-472./ National Recommendations of Cardiovascular Insufficiency Expert Association, Russian Cardiologic Society and Russian Scientific Medical Therapist Society on diagnostics and therapy of CCI (Revision Four). Serdechnaya Nedostatochnost Journal, 2013, 81 (7): 379- 472.


Просмотров: 294


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)